Spectrum Pharmaceuticals
Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company (founded 1987) that developed and commercialized oncology and hematology drugs including ROLVEDON, Rolontis, and poziotinib; it served US prescribers and partnered with Hanmi Pharmaceutical for ex-US markets before being acquired by Assertio in mid-2023.
- Company typePrivate
- Founded1987
- HeadquartersHenderson, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spectrum Pharmaceuticals does
Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company founded in 1987 that developed and commercialized oncology and hematology therapeutics. Its core product portfolio centered on ROLVEDON (eflapegrastim), a commercial-stage product whose launch was funded in 2022, alongside two investigational assets, Rolontis and poziotinib, both governed by licensing arrangements with South Korea-based Hanmi Pharmaceutical. The company's competitive positioning rested on late-stage oncology drug development, with portfolio expansion historically executed through acquisitions such as Talon Therapeutics (2013) and Allos Therapeutics (2012).
Operationally, Spectrum ran with 101–250 employees and followed a classic specialty-pharma business model: advance molecules through FDA-regulated clinical development, secure approval, and commercialize either through a focused US sales force or via licensing partners for ex-US markets. Revenue, where generated, came from product sales and licensing/royalty streams; however, the financial data as supplied appears corrupted at the unit level, and the company's multi-year EBITDA and net income figures indicate persistent operating losses consistent with a development-stage and early-commercial biotech. The September 2022 debt facility from SLR Capital Partners (up to $65 million, milestone-tranched) and the January 2022 $20 million equity investment from Hanmi Pharmaceutical were explicitly designed to fund the ROLVEDON launch and extend cash runway through 2024.
In mid-2023 Spectrum was acquired by Assertio, a strategic acquirer focused on pain and neurology therapeutics, with Spectrum shareholders receiving a combination of cash and stock. The transaction effectively took Spectrum private, ended its Nasdaq listing (ticker SPPI), and folded its oncology assets into Assertio's broader portfolio. As a result, Spectrum no longer operates as an independent company, and any forward-looking investment thesis must be evaluated through the lens of its parent, Assertio Holdings (which itself was announced in May 2026 as being acquired by Zydus Worldwide DMCC).
Spectrum Pharmaceuticals firmographics
Firmographics- Name
- Spectrum Pharmaceuticals
- Legal name
- Spectrum Pharmaceuticals Inc.
- Website
- https://sppirx.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Spectrum Pharmaceuticals was a Henderson, Nevada-based biopharmaceutical company (founded 1987) that developed and commercialized oncology and hematology drugs including ROLVEDON, Rolontis, and poziotinib; it served US prescribers and partnered with Hanmi Pharmaceutical for ex-US markets before being acquired by Assertio in mid-2023.
- Ownership category
- akta.pro rank
Spectrum Pharmaceuticals industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Spectrum Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Henderson
- HQ country
- United States
- HQ region
- North America
Markets served
Spectrum Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Spectrum Pharmaceuticals product offering
Product offeringCore offering
Spectrum Pharmaceuticals developed and commercialized oncology and hematology therapeutics, including Rolvedon (eflapegrastim), Rolontis, and poziotinib. The company focused on late-stage drug development for cancer treatment, operating in the US biopharmaceutical market. Its products were sold through specialty distribution and hospital channels for use in cancer care.
Product overview
Spectrum Pharmaceuticals was a Nasdaq-listed biotech focused on late-stage oncology drug development. The company developed drugs including Rolvedon (ROLVEDON), Rolontis, and poziotinib. Spectrum was acquired by Assertio in mid-2023 and ceased independent operations. No product portfolio details are available from current accessible sources.
Differentiator
Problem solved
Functional benefit
Brands
- ROLVEDON: Commercial product launched by Spectrum Pharmaceuticals, a drug for which the company secured financing for commercial launch
Products and services
- ROLVEDON (eflapegrastim)
- Rolontis (eflapegrastim-xnst)
- Poziotinib
Companies that use Spectrum Pharmaceuticals
Customer profileIdeal customer profiles1 record
Spectrum Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Spectrum Pharmaceuticals partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights3 records
Spectrum Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Salarius Pharmaceuticals: Small clinical-stage oncology biotech; comparable in scale and late-stage oncology drug development model.
- Jazz Pharmaceuticals: Specialty biopharma with significant oncology and hematology franchise; comparable in therapeutic focus, branded specialty drug development model, and late-stage oncology pipeline strategy.
- Eagle Pharmaceuticals: Small-cap specialty pharma focused on oncology and critical care injectables; directly comparable in scale, therapeutic focus on oncology supportive care, and branded specialty drug positioning.
- MEI Pharma: Clinical-stage oncology biotech developing hematology and solid tumor therapies; comparable in late-stage oncology pipeline profile and small-cap specialty focus.
- Helsinn Group: Private specialty pharma focused on oncology supportive care and cancer therapeutics; directly comparable to Spectrum's Rolvedon franchise in supportive care market.
- Aprea Therapeutics: Clinical-stage oncology biotech developing cancer therapies; comparable as a small-cap, late-stage oncology drug developer with similar pipeline risk profile.
- Cyclacel Pharmaceuticals: Small-cap oncology biotech developing hematology and solid tumor therapies; comparable in scale, oncology-only focus, and late-stage clinical pipeline model.
- G1 Therapeutics: Oncology-focused biotech with supportive care franchise (COSELA); highly comparable to Spectrum's Rolvedon positioning in chemotherapy-induced neutropenia supportive care.
Broad incumbents
- Amgen: Large established biopharma with deep oncology franchise and supportive care biologics (including pegfilgrastim via Neulasta); broader portfolio player whose oncology assets overlap with Spectrum's Rolvedon market.
- Bristol-Myers Squibb: Major oncology incumbent with broad hematology and solid tumor franchise; relevant comparable for Spectrum's oncology/hematology therapeutic positioning at scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Spectrum Pharmaceuticals social profiles
Digital presenceSpectrum Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spectrum Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Spectrum Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds9 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spectrum Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spectrum Pharmaceuticals
What does Spectrum Pharmaceuticals do?
Spectrum Pharmaceuticals developed and commercialized oncology and hematology therapeutics, including Rolvedon (eflapegrastim), Rolontis, and poziotinib. The company focused on late-stage drug development for cancer treatment, operating in the US biopharmaceutical market. Its products were sold through specialty distribution and hospital channels for use in cancer care.
Is Spectrum Pharmaceuticals a public or private company?
Spectrum Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Spectrum Pharmaceuticals founded?
Spectrum Pharmaceuticals was founded in 1987. It employs 101 to 250 people.
Where is Spectrum Pharmaceuticals based?
Spectrum Pharmaceuticals is headquartered in Henderson, United States, in the North America region.
Who are Spectrum Pharmaceuticals's main competitors?
Direct peers on record are Salarius Pharmaceuticals, Jazz Pharmaceuticals, Eagle Pharmaceuticals, MEI Pharma, Helsinn Group, Aprea Therapeutics, Cyclacel Pharmaceuticals and G1 Therapeutics. Broad incumbents are Amgen and Bristol-Myers Squibb.
Does Spectrum Pharmaceuticals have an API?
No public API is recorded for Spectrum Pharmaceuticals.
What industry is Spectrum Pharmaceuticals in?
Spectrum Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.